Skip to main navigation menu Skip to main content Skip to site footer

Narrative Review

Vol. 7 No. 1 (2003)

Advances in Tuberculosis Research in the Past 10 Years: Solutions for a Global Problem

  • Dick Menzies
  • Marcel Behr
November 6, 2020




  1. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. New Engl J Med 1992; 3264:231-235.
  2. Small PM, Hopewell PC, Singh SP, Paz A, Parsonnet J, Ruston DC et al. The epidemiology of tuberculosis in San Francisco: A population-based study using conventional and molecular methods. New Engl J Med 1994; 33024:1703-1709.
  3. Alland D, Kalkut GE, Moss AR, McAdam RA, Hahn JA, Bosworth W et al. Transmission of tuberculosis in New York City: An analysis by DNA fingerprinting and conventional epidemiologic methods. New Engl J Med 1994; 33024:17101716.
  4. Kulaga S, Behr M, Musana K, Brinkman J, Menzies D, Brassard P et al. Molecular epidemiology of tuberculosis in Montreal. CMAJ 2002; 1674:353-354.
  5. Godfrey-Faussett P, Sonnenberg P, Shearer SC, Bruce MC, Mee C, Morris L et al. Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet 2000; 3569235:1066-1071.
  6. Jasmer RM, Hahn JA, Small PM, Daley CL, Behr MA, Moss AR et al. A Molecular Epidemiologic Analysis of Tuberculosis Trends in San Francisco, 1991-1997. Ann Inter Med 1999; 130:971-978.
  7. Small P, Shafer R, Hopewell P. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993; 328:1137-1144.
  8. van Rie A, Warren R, Richardson M, Victor TC, Gie RP, Enarson DA et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 34116:1174-1179.
  9. Fine PE, Small PM. Exogenous reinfection in tuberculosis. N Engl J Med 1999; 34116:1226-1227.
  10. de Boer AS, van Soolingen D. Recurrent tuberculosis due to exogenous reinfection. N Engl J Med 2000; 34214:1050-1051.
  11. Caminero JA, Pena MJ, Campos-Herrero MI, Rodriguez JC, Garcia I, Cabrera P et al. Epidemiological Evidence of the Spread of a Mycobacterium tuberculosis Strain of the Beijing Genotype on Gran Canaria Island. AM J Resp Crit Care Med 2001; 164:1165-1170.
  12. Frieden T, Fujiwara P, Washko R, Hamburg M. Tuberculosis in New York City - Turning the TIde. The New England Journal of Medicine 1995; 3334:229-233.
  13. Frieden TR, Sherman LF, Maw KL, Fujiwara PI, Crawford JT, Nivin B et al. A multi-institutional outbreak of highly drugresistant tuberculosis. Epidemiology and clinical outcomes. JAMA 1996; 27615:1229-1235.
  14. U.S.Department of Health and Human Services PHS. Reported Tuberculosis in the United States, 2001: Tuberculosis Case Rates: United States, 2001. Center for Disease Control and Prevention, editor. 2001.
  15. Schluger NW, Rom WN. the polymerase chain reaction in the diagnosis and evaluation of pulmonary infections. Am J Respir Crit Care Med 1995; 152:11-16.
  16. Meuer S, Wittwer C, Nakagawara K. Rapid Cycle Real-Time PCR. Springer Verlag Berlin Heidelberg 2001.
  17. Walker DA, Taylor IK, Mitchell DM, Shaw RJ. Comparison of polymerase chain reaction amplification of two mycobacterial DNA sequences, IS6110 and the 65kDa antigen gene, in the diagnosis of tuberculosis. Thorax 1992; 47:690-694.
  18. Pfyffer GE, Kissling P, Jahn EMI, Welscher H-M, Salfinger M, Weber R. Diagnostic performance of amplified mycobacterium tuberculosis direct test with cerebrospinal fluid, other nonrespiratory, and respiratory specimens. Journal of Clinical Microbiology 1996; 344:834-841.
  19. Bradley SP, Reed SL, Catanzaro A. Clinical efficacy of the amplified mycobacterium tuberculosis direct test for the diagnosis of pulmonary tuberculosis. Am J Respir Crit Care Med 1996; 153:1606-1610.
  20. Cohen RA, Muzaffar S, Schwartz D, Bashir S, Luke S, McGartland LP et al. Diagnosis of pulmonary tuberculosis using PCR assays on sputum collected within 24 hours of hospital admission. Am J Respir Crit Care Med 1998; 157:156-161.
  21. Roos BR, van Cleeff MRA, Githui WA, Kivihya-Ndugga L, Odhiambo JA, Kibuga DK et al. Cost-effectiveness of the polymerase chain reaction versus smear examination for the diagnosis of tuberculosis in Kenya: a theoretical model. Int J Tuber Lung Dis 1997; 23:235-241.
  22. Anderson P, Munk ME, Pollock S, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356:1099-1104.
  23. Taha RA, Minshall EM, Olivenstein R, Ihaku D, Wallaert B, Tsicopoulos A et al. Increased Expression of IL-12 Receptor mRNA in Active Pulmonary Tuberculosis and Sarcoidosis. Am J Resp Crit Care Medicine 1999; 160:1119-1123.
  24. Zhang Y, Broser M, Cohen H, Bodkin M, Law K, Reibman J et al. Enhanced Interleukin-8 Release and Gene Expression in Macrophages after Exposure to Mycobacterium tuberculosis and Its Components. J Clin Invest 1995; 95:586-592.
  25. Surcel HM, Troye-Blomberg M, Paulie S, Anderson G, Moreno C, Passvol G et al. TD1/TD2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens. Immunology 1994; 81:171-176.
  26. Mazurek G, LoBue PA, Daley CL, Bernardo J, Lardizabal AA, Bishai WR. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001; 25614:1740-1747.
  27. Laurens A.H.van Pixteren, Ravn P, Agger EM, Pollock J, Andersen P. Diagnosis of Tuberculosis Based on the Two Specific Antigens ESAT-6 and CFP10. Clinical & Diagnostic Labratory Immunology 2000; 72:155-160.
  28. Johnson PDR, Stuart RL, Grayson ML, Olden D, Clancy A, Ravn P et al. Tuberculin-Purified Protein Derivative-, MPT-64-, and ESAT-6-Stimulated Gamma Interferon Responses in Medical Students before and after Mycobacterium bovis BCG Vaccination and in Patients with Tuberculosis. Clinical & Diagnostic Labratory Immunology 1999; 66:934-937.
  29. Sorensen AL, Nagai S, Houen G, Andersen P, Andersen AB. Purification and Characterization of a Low-Molecular-Mass TCell Antigen Secreted by Mycobacterium Tuberculosis. Infection and Immunity 1995; 635:1710-1717.
  30. Ulrichs T, Anding P, Porcelli S, Kaufmann SHE, Munk ME. Increased Numbers of ESAT-6 and Purified Protein Derivative-Specific Gamma Interferon-Producing Cells in Subclinical and Active Tuberculosis Infection. Infection and Immunity 2000; 6810:6073-6076.
  31. Lipsky PE, Heijde D, St.Clair W, Furst DE, Breedveld FC, Kalden JR et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. The New England Journal of Medicine 2000; 34322:1594-1602.
  32. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al. Tuberculosis associated with infliximab, a tumor necrosis factor a - neutralizing agent. The New England Journal of Medicine 2001; 34515:1098-1104.
  33. Fox W. The current status of short-course chemotherapy. Bull Int Union Tuberc 1978; 534:1-13.
  34. ten Dam HG, Toman K, Hitze KL, Guld J. Present knowledge of immunization against tuberculosis. Bulletin of the World Health Organization 1976; 54:255-267.
  35. Comstock GW. Identification of an effective vaccine against tuberculosis. Am Rev Resp Dis 1988; 138:479-480.
  36. The Tuberculosis Prevention Trial M. Trial of BCG vaccines in south India for Tuberculosis prevention: first report. Bulletin of the World Health Organization 1979; 575:819-827.
  37. Mostowy S, Cousins D, Brinkman J, Aranaz A, Behr MA. Genomic deletions suggest a phylogeny for the Mycobacterium tuberculosis complex. J Infect Dis 2002; 1861:74-80.
  38. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic' S. Recombinant bacillus calmette-guerin BCG vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci 2000; 9725:13853-13858.
  39. Horwitz MA, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in th Guinea Pig Model of Pulmonary Tuberculosis. Infect Immun 2003; 714:1672-1679.
  40. Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003; 95:533-539.
  41. Gordin FM, Chiasson RE, Matts JP, et al. Rifampin and Pyrazinamide vs Isoniazid for Prevention of tuberculosis in HIV-infected Persons. JAMA 2000; 28311:1445-1450.
  42. Center for Disease Control. Fatal and Severe Hepatitis Associated with Rifampin and Pyrazinamide for the Treatment of Latent Tuberculosis Infection - New York and Georgia, 2000. MMWR 2001; 5015:289-291.
  43. Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in the American Thoracic Society / CDC recommendations. MMWR 2001; 5034:733-735.
  44. McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and Rifampin vs Isoniazid for the Treatment of Latent Tuberculosis. Chest 2003; 123:102-106.
  45. Stout JE, Engemann JJ, Cheng AC, Fortnberry ER, Hamilton CD. Safety of 2 Months of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis. Am J Crit Care Med 2003; 167:824-827.
  46. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002; 137:640-647.
  47. Rieder HL. Interventions for Tuberculosis COntrol and Elimination. International Union Against Tuberculosis and Lung Disease 2002.
  48. Enarson DA, Rieder HL, Arnadottir T, Trebucq A. Tuberculosis guide for low income countries. Tuberculosis guide for low income countries. Paris: International Union Against Tuberculosis and Lung Disease, 2000.
  49. Murray CJL, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Against Tuberculosis 1990; 651:2-20.
  50. Suarez PG, Watt CJ, Alarcon E, Portocarrero J, Zavala D, Canales R et al. The Dynamics of Tuberculosis in Response to 10 Years of Intensive Control Effort in Peru. The Journal of Infectious Diseases 2001; 184:473-478.
  51. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F et al. Global surveillance for antituberculosisdrug resistance. 1994-1997. N Engl J Med 1998; 338:16411649.
  52. Weis S, Slocum PC, Blais FX, King B, Nunn M, Matney B et al. The effect of directly observed therapy on the rates of drug resistant and relapse in tuberculosis. New Engl J Med 1994; 33017:1179-1184.


Download data is not yet available.

Similar Articles

1 2 > >> 

You may also start an advanced similarity search for this article.